(ASPN) Aspen Aerogels - Overview
Sector: Industrials | Industry: Building Products & Equipment | Exchange: NYSE (USA) | Market Cap: 480m USD | Total Return: 7.4% in 12m
Avg Turnover: 10.0M
Qual. Beats: 0
Rev. Trend: 38.8%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -8.3 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -12.99 < 1.0 - financial distress zone
Fakeout
Tailwinds
Supp Ema8, Rs Leader, Idiosyncratic Leader
Aspen Aerogels, Inc. (ASPN) specializes in the design and manufacture of aerogel-based insulation and thermal management solutions. The company operates across two primary segments: Thermal Barrier and Energy Industrial. Its product portfolio, including brands such as PyroThin, Pyrogel, and Cryogel, addresses high-performance needs in electric vehicle (EV) battery safety, sub-ambient cryogenic systems, and high-temperature petrochemical processing.
The business model leverages the unique material properties of aerogels-which are among the worlds lowest density solids-to provide superior thermal resistance in space-constrained environments. While classified under Oil & Gas Equipment & Services, the company is increasingly exposed to the EV sector, where thermal barriers are critical for preventing thermal runaway in lithium-ion battery packs. Investors may find additional data-driven insights on these sector transitions by exploring ValueRay.
- Rising EV battery thermal barrier demand drives significant revenue growth trajectories
- General Motors supply agreement milestones impact near-term production and cash flow
- Energy industrial segment margins remain sensitive to global petrochemical capital expenditure
- Raw material cost volatility and manufacturing scale-up efficiency influence operating profitability
- Expansion of manufacturing capacity in Georgia dictates long-term capital allocation strategy
| Net Income: -112.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 9.47 > 1.0 |
| NWC/Revenue: 71.55% < 20% (prev 60.07%; Δ 11.48% < -1%) |
| CFO/TA 0.15 > 3% & CFO 61.4m > Net Income -112.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.7m) vs 12m ago 0.82% < -2% |
| Gross Margin: 11.93% > 18% (prev 0.39%; Δ 1.15k% > 0.5%) |
| Asset Turnover: 47.70% > 50% (prev 78.73%; Δ -31.03% > 0%) |
| Interest Coverage Ratio: -8.29 > 6 (EBITDA TTM -52.8m / Interest Expense TTM 11.9m) |
| A: 0.40 (Total Current Assets 252.5m - Total Current Liabilities 87.8m) / Total Assets 410.5m |
| B: -2.62 (Retained Earnings -1.07b / Total Assets 410.5m) |
| C: -0.20 (EBIT TTM -98.6m / Avg Total Assets 482.7m) |
| D: -5.45 (Book Value of Equity -1.07b / Total Liabilities 197.0m) |
| Altman-Z'' = -12.99 = D |
| DSRI: 0.89 (Receivables 36.4m/77.4m, Revenue 230.3m/436.9m) |
| GMI: 3.27 (GM 11.93% / 39.04%) |
| AQI: 8.25 (AQ_t 0.10 / AQ_t-1 0.01) |
| SGI: 0.53 (Revenue 230.3m / 436.9m) |
| TATA: -0.42 (NI -112.0m - CFO 61.4m) / TA 410.5m) |
| Beneish M = 2.47 (Cap -4..+1) = D |
As of May 30, 2026, the stock is trading at USD 6.40 with a total of 1,605,948 shares traded.
Over the past week, the price has changed by +17.00%,
over one month by +77.29%,
over three months by +105.13% and
over the past year by +7.38%.
Aspen Aerogels has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy ASPN.
- StrongBuy: 4
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 6.4 | -0.8% |
P/E Forward = 714.2857
P/S = 2.084
P/B = 2.2476
Revenue TTM = 230.3m USD
EBIT TTM = -98.6m USD
EBITDA TTM = -52.8m USD
Long Term Debt = 68.3m USD (from longTermDebt, last quarter)
Short Term Debt = 34.3m USD (from shortTermDebt, last quarter)
Debt = 165.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 36.3m
Net Debt = -10.5m USD (calculated: Debt 165.1m - CCE 175.6m)
Enterprise Value = 469.4m USD (479.9m + Debt 165.1m - CCE 175.6m)
Interest Coverage Ratio = -8.29 (Ebit TTM -98.6m / Interest Expense TTM 11.9m)
EV/FCF = 13.20x (Enterprise Value 469.4m / FCF TTM 35.6m)
FCF Yield = 7.58% (FCF TTM 35.6m / Enterprise Value 469.4m)
FCF Margin = 15.45% (FCF TTM 35.6m / Revenue TTM 230.3m)
Net Margin = -48.64% (Net Income TTM -112.0m / Revenue TTM 230.3m)
Gross Margin = 11.93% ((Revenue TTM 230.3m - Cost of Revenue TTM 202.8m) / Revenue TTM)
Gross Margin QoQ = 11.29% (prev -55.47%)
Tobins Q-Ratio = 1.14 (Enterprise Value 469.4m / Total Assets 410.5m)
Interest Expense / Debt = 7.21% (Interest Expense 11.9m / Debt 165.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -77.9m (EBIT -98.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.88 (Total Current Assets 252.5m / Total Current Liabilities 87.8m)
Debt / Equity = 0.77 (Debt 165.1m / totalStockholderEquity, last quarter 213.5m)
Debt / EBITDA = 0.20 (negative EBITDA) (Net Debt -10.5m / EBITDA -52.8m)
Debt / FCF = -0.29 (Net Debt -10.5m / FCF TTM 35.6m)
Total Stockholder Equity = 265.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.20% (Net Income -112.0m / Total Assets 410.5m)
RoE = -8.36% (Net Income TTM -112.0m / Total Stockholder Equity 1.34b)
RoCE = -7.01% (EBIT -98.6m / Capital Employed (Equity 1.34b + L.T.Debt 68.3m))
RoIC = -21.91% (negative operating profit) (NOPAT -77.9m / Invested Capital 355.6m)
WACC = 10.30% (E(479.9m)/V(645.0m) * Re(11.88%) + D(165.1m)/V(645.0m) * Rd(7.21%) * (1-Tc(0.21)))
Discount Rate = 11.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 7.70%
[DCF] Terminal Value 68.92% ; FCFF base≈35.6m ; Y1≈35.7m ; Y5≈37.8m
[DCF] Fair Price = 5.46 (EV 442.0m - Net Debt -10.5m = Equity 452.5m / Shares 82.9m; r=10.30% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.16 | # QB: 0
Revenue Correlation: 38.82 | Revenue CAGR: 13.85% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.20 | Chg30d=+4.91% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=+31.55% | Revisions=+43% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.68 | Chg30d=+12.12% | Revisions=+43% | GrowthEPS=-39.5% | GrowthRev=-27.6%
EPS next Year (2027-12-31): EPS=-0.07 | Chg30d=N/A | Revisions=+33% | GrowthEPS=+89.0% | GrowthRev=+44.7%
[Analyst] Revisions Ratio: +43%